|
|
The increasing scrutiny over the cost of biopharmaceuticals, combined with the need to bring lifesaving therapies to emerging regions, requires businesses to balance social and financial needs while driving patient access. Utilizing standardized approaches to biomanufacturing can lower costs, improve outcomes, and alter the landscape of the global pharmaceutical market.
|